Ignite Creation Date:
2025-12-24 @ 3:31 PM
Ignite Modification Date:
2026-02-23 @ 12:22 PM
Study NCT ID:
NCT00328692
Status:
COMPLETED
Last Update Posted:
2009-10-09
First Post:
2006-05-19
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
PROTECT-1: A Study of the Selective A1 Adenosine Receptor Antagonist KW-3902 for Patients Hospitalized With Acute HF and Volume Overload to Assess Treatment Effect on Congestion and Renal Function
Sponsor:
NovaCardia, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
CKI-301
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
None
Responsible Party Affiliation:
Old Name:
Executive Vice President, Clinical and Quantitative Sciences
Old Organization:
Merck & Co., Inc.
Collaborators
Collaborators
| Name | Class | View |
|---|---|---|
| None | INDUSTRY | View |